Solid Biosciences Inc. Derivative Liability, Current
Solid Biosciences Inc. (SLDB) had Derivative Liability, Current of $4.20 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DerivativeLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Derivative Liability, Current $4.20M.
- 2026-03-31: Derivative Liability, Current $3.35M.
- 2025-12-31: Derivative Liability, Current $9.20M.
- 2025-09-30: Derivative Liability, Current $6.55M.
| Period end | Derivative Liability, Current |
|---|---|
| 2026-06-30 | $4.20M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $3.35M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $9.20M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $6.55M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $5.70M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $4.80M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $3.15M 10-K · filed 2026-03-19 |
| 2024-09-30 | $3.40M 10-Q · filed 2024-11-06 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |